Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Medistep Healthcare's Days Sales Outstanding for the
six
months ended in Sep. 2025 was 147.58.
Medistep Healthcare's Days Inventory for the
six
months ended in Sep. 2025 was 18.
Medistep Healthcare's Days Payable for the
six
months ended in Sep. 2025 was 18.25.
Therefore, Medistep Healthcare's Cash Conversion Cycle (CCC) for the
six
months ended in Sep. 2025 was 147.33.
Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.
Be Aware
CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.
The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.
Medistep Healthcare Cash Conversion Cycle Related Terms
Medistep Healthcare Cash Conversion Cycle Historical Data
* Premium members only.
The historical data trend for Medistep Healthcare's Cash Conversion Cycle can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:MEDISTEP vs MCK, CAH, COR: Cash Conversion Cycle Comparison
For the Medical Distribution subindustry, Medistep Healthcare's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medistep Healthcare Cash Conversion Cycle vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Medistep Healthcare's Cash Conversion Cycle distribution charts can be found below:
* The bar in red indicates where Medistep Healthcare's Cash Conversion Cycle falls into.
Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.
Cash Conversion Cycle is one of several measures of management effectiveness.
Medistep Healthcare's Cash Conversion Cycle for the fiscal year that ended in Mar. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medistep Healthcare (NSE:MEDISTEP) has a Cash Conversion Cycle of 147.33 as of Sep. 2025. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Medistep Healthcare and its competitors.
Is Medistep Healthcare's Cash Conversion Cycle too high?
Medistep Healthcare's current Cash Conversion Cycle is 147.33. The Medical Distribution industry median Cash Conversion Cycle is 52.15. Medistep Healthcare's value of 147.33 is 182.5% above this industry median. Overall, Medistep Healthcare has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Medistep Healthcare's Cash Conversion Cycle compare to MCK and CAH?
Medistep Healthcare's Cash Conversion Cycle of 147.33 can be compared against companies in the Medical Distribution industry. The industry median Cash Conversion Cycle is 52.15. Medistep Healthcare's value of 147.33 is 182.5% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Conversion Cycle for a Medical Distribution company?
The median Cash Conversion Cycle among Medical Distribution companies is 52.15, based on 117 companies in the industry. Companies in the top quartile (top 25%) have a Cash Conversion Cycle significantly above this median, while those in the bottom quartile fall well below. However, Cash Conversion Cycle should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medistep Healthcare's current Cash Conversion Cycle of 147.33 is 182.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Conversion Cycle mean?
A high Cash Conversion Cycle can signal that a stock is expensive relative to its fundamentals. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Medistep Healthcare and its competitors. For the Medical Distribution industry, the median Cash Conversion Cycle is 52.15 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medistep Healthcare's current Cash Conversion Cycle is 147.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medistep Healthcare stock overvalued right now?
Medistep Healthcare (NSE:MEDISTEP) has a current Cash Conversion Cycle of 147.33. The current Cash Conversion Cycle is 147.33 and 182.5% above the Medical Distribution industry median of 52.15. Medistep Healthcare's overall GF Score™ is 19/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Conversion Cycle calculated?
Cash Conversion Cycle is calculated from a company's financial statements. For Medistep Healthcare (NSE:MEDISTEP), the current Cash Conversion Cycle is 147.33 as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Medistep Healthcare Ltd operates in the pharmaceutical and healthcare product sectors. Its business includes manufacturing intimate care and hygiene products such as sanitary pads, as well as nutraceutical products like energy powders. The company also trades a variety of pharmaceutical, surgical, and medical equipment products. Medistep Healthcare's operations focus mainly on the western region of India, particularly in Gujarat. Its Core business activity is divided into the following categories: a) Trading of Pharmaceutical & Surgical products, b) Trading & Manufacturing of Nutraceuticals and Intimate care & hygiene products. The company generates the majority of its revenue from Trading and distribution.
19GF Score
Get the complete analysis for NSE:MEDISTEP
Cash Conversion Cycle is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:MEDISTEP has been successfully added to your 
